| Literature DB >> 31485537 |
Hanine Hadni1, Menana Elhallaoui1.
Abstract
Plasmodium falciparum dihydrofolate reductase (pf-DHFR) is one of the several targets in the treatment of malaria. Double and quadruple mutations at residues 51, 59, 108, and 164 of pf-DHFR have been linked to antifolate resistance. Several efforts are underway to overcome this drug resistance and to produce potential inhibitors. In this regard, the quantitative structure-activity relationship (QSAR) and docking studies were performed for previously reported 4-anilinoquinoline and 1,3,5-triazines based molecular hybrids. The generated model showed good correlation coefficients (R2 = 0.70) and test set prediction coefficient (R2 = 0.74). These outcomes showed the good predictive competence of the established QSAR model. Based on these results we docked into active site of pf-DHFR protein with the most active (4) and the less active (5) compounds. The docking results revealed that these molecules interact specifically with SER108 and ILE164 in the pf-DHFR binding pocket as that of best active compound but also showed additional interactions with LEU40 and GLY44.Entities:
Keywords: 4-Anilinoquinoline-triazine; Antimalarial activity; Molecular docking; Pharmaceutical chemistry; QSAR; Theoretical chemistry; pf-DHFR
Year: 2019 PMID: 31485537 PMCID: PMC6717158 DOI: 10.1016/j.heliyon.2019.e02357
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Fig. 1The structure of the 4-anilinoquinoline-triazine derivatives.
Studied compounds and their observed activities logIC50.
| Compounds | R1 | R2 | IC50(obs) | LogIC50(obs) |
|---|---|---|---|---|
| 1 | 3-fluoroanilinyl | 4-methylpiperazin-1-yl | 22.80 | 1.358 |
| 2 | 3-fluoroanilinyl | 4-ethylpiperazin-1-yl | 2.47 | 0.393 |
| 3 | 3-fluoroanilinyl | 2-morpholinoethan-1-aminyl | 40.02 | 1.602 |
| 4 | 3-fluoroanilinyl | 3-morpholinopropan-1-aminyl | 1.36 | 0.134 |
| 5 | 3-fluoroanilinyl | piperidin-1-yl | 128.74 | 2.110 |
| 6 | 4-fluoroanilinyl | 4-methylpiperazin-1-yl | 8.97 | 0.953 |
| 7 | 4-fluoroanilinyl | 4-ethylpiperazin-1-yl | 11.11 | 1.046 |
| 8 | 4-fluoroanilinyl | 2-morpholinoethan-1-aminyl | 9.81 | 0.992 |
| 9 | 4-fluoroanilinyl | 3-morpholinopropan-1-aminyl | 15.82 | 1.199 |
| 10 | 4-fluoroanilinyl | piperidin-1-yl | 41.75 | 1.621 |
| 11 | 3-chloroanilinyl | 4-methylpiperazin-1-yl | 2.41 | 0.382 |
| 12 | 3-chloroanilinyl | 4-ethylpiperazin-1-yl | 2.11 | 0.324 |
| 13 | 3-chloroanilinyl | 2-morpholinoethan-1-aminyl | 30.60 | 1.486 |
| 14 | 3-chloroanilinyl | 3-morpholinopropan-1-aminyl | 3.82 | 0.582 |
| 15 | 4-chloroanilinyl | 4-methylpiperazin-1-yl | 7.80 | 0.892 |
| 16 | 4-chloroanilinyl | 4-ethylpiperazin-1-yl | 4.14 | 0.617 |
| 17 | 4-chloroanilinyl | 3-morpholinopropan-1-aminyl | 4.63 | 0.666 |
| 18 | 3-methoxyanilinyl | 4-methylpiperazin-1-yl | 4.26 | 0.629 |
| 19 | 3-methoxyanilinyl | 4-ethylpiperazin-1-yl | 8.90 | 0.949 |
| 20 | 3-methoxyanilinyl | 3-morpholinopropan-1-aminyl | 2.98 | 0.474 |
| 21 | 4-methoxyanilinyl | 4-ethylpiperazin-1-yl | 4.26 | 0.629 |
| 22 | 4-methoxyanilinyl | 3-morpholinopropan-1-aminyl | 3.81 | 0.581 |
| 23 | 3,4-dimethoxyanilinyl | 4-methylpiperazin-1-yl | 5.04 | 0.702 |
| 24 | 3,4-dimethoxyanilinyl | 4-ethylpiperazin-1-yl | 2.58 | 0.412 |
| 25 | 3,4-dimethoxyanilinyl | 3-morpholinopropan-1-aminyl | 4.58 | 0.661 |
| 26 | 1,2,3,4-tetrahydroquinolinyl | 4-methylpiperazin-1-yl | 12.64 | 1.102 |
| 27 | 1,2,3,4-tetrahydroquinolinyl | 4-ethylpiperazin-1-yl | 20.84 | 1.319 |
| 28 | 1,2,3,4-tetrahydroquinolinyl | 2-morpholinoethan-1-aminyl | 17.35 | 1.239 |
| 29 | 1,2,3,4-tetrahydroquinolinyl | 3-morpholinopropan-1-aminyl | 14.70 | 1.167 |
| 30 | 1,2,3,4-tetrahydroisoquinolin-2(1H)-yl | 4-methylpiperazin-1-yl | 28.12 | 1.449 |
| 31 | 1,2,3,4-tetrahydroisoquinolin-2(1H)-yl | 4-ethylpiperazin-1-yl | 12.12 | 1.084 |
| 32 | 1,2,3,4-tetrahydroisoquinolin-2(1H)-yl | 2-morpholinoethan-1-aminyl | 45.21 | 1.655 |
| 33 | 1,2,3,4-tetrahydroisoquinolin-2(1H)-yl | 3-morpholinopropan-1-aminyl | 20.32 | 1.308 |
| 34 | morpholinyl | 4-methylpiperazin-1-yl | 3.22 | 0.508 |
| 35 | morpholinyl | 4-ethylpiperazin-1-yl | 2.16 | 0.334 |
| 36 | morpholinyl | 2-morpholinoethan-1-aminyl | 5.87 | 0.769 |
| 37 | morpholinyl | 3-morpholinopropan-1-aminyl | 2.76 | 0.441 |
List of the calculate descriptors.
| Type of descriptors | Electronic | lipophilic | Geometrical | physicochemical | Steric |
|---|---|---|---|---|---|
| Name of the descriptors | HOMO energy (EHOMO) | lipophilic (Octanol-water partition coefficient) (LogP) | Torsion energy (T) | Critical pressure (CP) | Density (D) |
The values of selected descriptors and observed/predicted activity (logIC50).
| N | E | S–B | T | EVDW | LogP | ST | LogIC50 (Obs) | MLR | ANN | Cv(LOO) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | -2213.007 | 0.520 | -15.547 | 42.004 | 7.347 | 72.100 | 0.393 | 0.7412 | 0.724 | 0.739 | |
| 3 | -2288.181 | 0.532 | -12.073 | 43.096 | 6.065 | 77.900 | 1.602 | 1.1958 | 1.311 | 1.299 | |
| 4 | -2327.486 | 0.556 | -12.039 | 43.729 | 6.170 | 75.700 | 0.134 | 0.8582 | 0.667 | 0.772 | |
| 5 | -2118.390 | 0.371 | -15.879 | 39.069 | 7.986 | 76.600 | 2.110 | 2.1119 | 2.099 | 2.100 | |
| 7 | -2213.006 | 0.522 | -15.540 | 42.003 | 7.347 | 72.100 | 1.046 | 0.7385 | 0.725 | 0.737 | |
| 8 | -2288.181 | 0.534 | -12.048 | 43.091 | 6.065 | 77.900 | 0.992 | 1.1959 | 1.310 | 1.298 | |
| 9 | -2327.485 | 0.558 | -12.034 | 43.726 | 6.170 | 75.700 | 1.199 | 0.8560 | 0.665 | 0.769 | |
| 11 | -2534.064 | 0.483 | -15.753 | 41.898 | 7.409 | 76.700 | 0.382 | 0.7792 | 0.649 | 0.628 | |
| 12 | -2573.369 | 0.533 | -15.553 | 42.645 | 7.747 | 73.800 | 0.324 | 0.5348 | 0.473 | 0.472 | |
| 13 | -2648.544 | 0.545 | -12.055 | 43.739 | 6.465 | 79.600 | 1.486 | 0.9925 | 1.416 | 1.288 | |
| 14 | -2687.848 | 0.570 | -12.044 | 44.369 | 6.570 | 77.400 | 0.582 | 0.6502 | 0.629 | 0.740 | |
| 15 | -2534.064 | 0.485 | -15.692 | 41.838 | 7.409 | 76.700 | 0.892 | 0.7776 | 0.641 | 0.625 | |
| 16 | -2573.369 | 0.533 | -15.557 | 42.558 | 7.747 | 73.800 | 0.617 | 0.5202 | 0.461 | 0.464 | |
| 18 | -2188.972 | 0.518 | -15.798 | 44.081 | 6.724 | 73.200 | 0.629 | 0.7116 | 0.675 | 0.678 | |
| 19 | -2228.277 | 0.571 | -15.560 | 44.843 | 7.062 | 70.600 | 0.949 | 0.5258 | 0.762 | 0.761 | |
| 20 | -2342.756 | 0.624 | -12.094 | 46.444 | 5.886 | 74.100 | 0.474 | 0.5699 | 0.495 | 0.515 | |
| 21 | -2228.275 | 0.578 | -15.558 | 44.824 | 7.062 | 70.600 | 0.629 | 0.5114 | 0.764 | 0.756 | |
| 22 | -2342.754 | 0.615 | -12.040 | 46.569 | 5.886 | 74.100 | 0.581 | 0.6138 | 0.527 | 0.550 | |
| 23 | -2303.447 | 0.477 | -13.677 | 47.151 | 6.598 | 70.600 | 0.702 | 0.7632 | 0.718 | 0.768 | |
| 25 | -2457.232 | 0.593 | -9.705 | 49.569 | 5.759 | 71.600 | 0.661 | 0.6775 | 0.659 | 0.611 | |
| 26 | -2191.186 | 0.989 | -15.240 | 49.085 | 7.482 | 71.700 | 1.102 | 1.2207 | 1.110 | 1.177 | |
| 27 | -2230.491 | 1.046 | -14.930 | 49.892 | 7.820 | 69.200 | 1.319 | 1.0648 | 1.320 | 1.174 | |
| 28 | -2305.667 | 1.058 | -11.375 | 51.018 | 6.538 | 74.400 | 1.239 | 1.4323 | 1.243 | 1.280 | |
| 30 | -2191.189 | 0.605 | -15.188 | 46.528 | 7.381 | 71.700 | 1.449 | 1.3842 | 1.403 | 1.300 | |
| 31 | -2230.494 | 0.660 | -14.869 | 47.331 | 7.719 | 69.200 | 1.084 | 1.2315 | 1.108 | 1.204 | |
| 32 | -2305.670 | 0.669 | -11.361 | 48.401 | 6.437 | 74.400 | 1.655 | 1.5870 | 1.661 | 1.600 | |
| 34 | -2074.665 | 0.796 | -6.763 | 43.187 | 5.271 | 72.000 | 0.508 | 0.5254 | 0.508 | 0.392 | |
| 35 | -2113.970 | 0.851 | -6.497 | 43.975 | 5.609 | 69.300 | 0.334 | 0.3270 | 0.356 | 0.390 | |
| 37 | -2228.449 | 0.885 | -3.101 | 45.637 | 4.433 | 72.900 | 0.441 | 0.4175 | 0.436 | 0.427 | |
Fig. 2Modeling characterization by the normalized coefficients.
Fig. 3The correlation between the observed and the predicted activities.
Fig. 4The correlation between the observed and the predicted activities established by ANN.
Fig. 5Correlation of observed and predicted activities calculated using Cross-Validation (LOO).
Calculated results using Y-randomization.
| N | 4 | 23 | 5 | 26 | 30 | 37 | 2 | 32 | 24 | 21 | 28 | 9 | 7 | 20 | 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| logIC50 | 0.134 | 0.702 | 2.110 | 1.102 | 1.449 | 0.441 | 0.393 | 1.655 | 0.412 | 0.629 | 1.239 | 1.199 | 1.046 | 0.474 | 0.382 |
| pred logIC50 | 0.869 | 0.732 | 2.102 | 1.254 | 1.368 | 0.401 | 0.774 | 1.534 | 0.588 | 0.543 | 1.428 | 0.867 | 0.772 | 0.585 | 0.802 |
| N | 36 | 1 | 27 | 25 | 16 | 19 | 13 | 31 | 8 | 12 | 34 | 17 | 33 | 15 | - |
| logIC50 | 0.769 | 1.358 | 1.319 | 0.661 | 0.617 | 0.949 | 1.486 | 1.084 | 0.992 | 0.324 | 0.508 | 0.666 | 1.308 | 0.892 | - |
| pred logIC50 | 0.716 | 1.032 | 1.080 | 0.610 | 0.528 | 0.556 | 0.980 | 1.196 | 1.211 | 0.541 | 0.545 | 0.626 | 1.261 | 0.800 | - |
The results of external validation by the MLR and ANN methods.
| N | LogIC50 | Pred (LogIC50) MLR | Residual | Pred (LogIC50) | Residual |
|---|---|---|---|---|---|
| 1 | 1.358 | 0.99 | 0.388 | 0.776 | 0.443 |
| 6 | 0.953 | 0.984 | -0.013 | 0.769 | 0.042 |
| 10 | 1.621 | 2.119 | -0.158 | 2.099 | -0.109 |
| 17 | 0.666 | 0.65 | -0.061 | 0.611 | -0.146 |
| 24 | 0.412 | 0.646 | -0.312 | 0.525 | -0.347 |
| 29 | 1.167 | 1.155 | 0.079 | 1.014 | 0.106 |
| 33 | 1.308 | 1.326 | 0.097 | 1.393 | 0.013 |
| 36 | 0.769 | 0.736 | -0.02 | 0.544 | -0.002 |
Golbraikh and Tropsha criteria.
| Parameter | Formula | Threshold | Modelscore |
|---|---|---|---|
| 0.68 | |||
| r2 | Coefficient of determination for the plot of predicted versus observed for test set by MLR | r2 > 0.6 | 0.74 |
| r2 at zero intercept | 0.67 | ||
| r2 for the plot of observed versus predicted activity for the test set at zero intercept | 0.68 | ||
| 0.01 | |||
| k | Slope of the plot of predicted versus observed activity for test set at zero intercept | 0.85 < k < 1.15 | 0.92 |
| 0.07 | |||
| k’ | Slope of the plot of observed versus predicted activity at zero intercept | 0.85 < k’<1.15 | 0.93 |
| 0.08 |